The pertinence of this experimental intervention is supported by the fact that a phase II clinical trial has been approved and initiated, applying intracerebroventricular recombinant VEGF in ALS patients [65] (ClinicalTrials.gov NCT01384162 (accessed on 7 February 2023)). This evidence concerns the gene VEGFA and amyotrophic lateral sclerosis.